The accumulation of CD96 in NK cells in hepatocellular carcinoma patients disrupts the balance between these three receptors, which subsequently results in NK cell dysfunction and exhaustion (65); therefore, careful examination of the CD96-TIGIT-CD226 system should be involved in developing immunotherapies targeting these receptors. The gene discussed is CD226; the disease is hepatocellular carcinoma.